Wednesday, April 18, 2018

Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

Grant Expected to Fund Development of OPNT003 to NDA Ready Stage

SANTA MONICA, Calif., April 18, 2018 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it has been awarded a grant of approximately $7.4 million from the National Institutes of Health’s National Institute on Drug Abuse (NIDA) for the development of OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose. The grant includes approximately $2.6 million to be funded for the period ending March 31, 2019, with the balance to be funded over the subsequent two years.

“We view this NIDA grant as further validation of the potential for OPNT003 to be an important treatment for opioid overdose, a growing U.S. health epidemic,” said Roger Crystal, M.D., Chief Executive Officer of Opiant.  “Fentanyl was responsible for more overdose deaths (in excess of 20,000) than either heroin or prescription opioids in 2016.  Recognizing the evolution of the opioid crisis, the National Institutes of Health has called for the development of stronger, longer-acting overdose reversal products in order to address this next wave of potent synthetic opioids, like fentanyl. We look forward to using this grant to continue the development of OPNT003.”

“The receipt of this grant is reflective of our aim to maximize non-dilutive financing to support our research and development programs,” said David O’Toole, Chief Financial Officer of Opiant. “Over the last five months, we have also announced the return of our royalty stream from Adapt Pharmaceuticals and the receipt of funds from the exercise of warrants, which have further strengthened our balance sheet.”

The grant follows encouraging data from a Phase I clinical study of OPNT003 and a subsequent recent meeting with the U.S. Food & Drug Administration (FDA).  Based on FDA feedback, Opiant intends to pursue a 505(b)(2) development path and anticipates the potential to submit a New Drug Application (NDA) for the drug and intranasal delivery device combination in 2020. The 505(b)(2) development path allows certain information required for NDA approval to be derived from studies not conducted by Opiant.  Nalmefene for injection was previously approved by the FDA for treating suspected or confirmed opioid overdose.

Opiant was awarded this grant, to be funded over the next three years, following an in-depth evaluation by NIDA of the Company’s proposed research for scientific and technical merit. Opiant retains full commercial rights to OPNT003.

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions. The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Opiant’s first product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by its partner, Adapt Pharmaceuticals. For more information please visit: www.opiant.com.

Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

CONTACTS:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
(617) 535-7746

Source link

N4 Pharma Starts Clinical Trial Of Reformulated Sildenafil

Share this

LONDON (Alliance News) – N4 Pharma PLC said Wednesday that it has commenced proof of concept clinical trial for erectile dysfunction treatment drug sildenafil, following the completion of the validation of the reformulated drug.

The pharmaceutical company said the trial will comprise a four way crossover study in 12 healthy subjects comparing N4 Pharma’s reformulated 100 milligram sildenafil to Viagra 50 milligram in both fed and fasted conditions. The trial is expected to take eight to 10 weeks with provisional results data available in July, with the final clinical study report expected at the end of August.

N4 Pharma said the trial will enable the company to establish whether its reformulation has been sufficiently successful to allow N4 Pharma to prepare for a pre-IND meeting with the FDA towards the end of this year or whether further amendments are required to optimise efficacy.

“The board continues to believe that the improvements sought to be evidenced through the Trial will make our reformulation that much more attractive to both the end consumer and pharmaceutical partners in the final development and commercialisation of the drug in this highly lucrative market,” said Chief Executive Nigel Theobald.

Shares in N4 Pharma were trading 1.0% higher at 22.96 pence Wednesday.

By Tapan Panchal; [email protected]

Copyright 2018 Alliance News Limited. All Rights Reserved.

Source link

Best Practices for Analyzing Pesticides and Their Metabolites in Environmental Samples

When a company wishes to commercialize a new pesticide, they must conduct environmental studies and develop analytical methods capable of detecting the pesticide, and its metabolites, in soil and water samples. The methods must be robust and rugged, for easy use in routine analysis. James Stry, a principal investigator at FMC Agricultural Solutions, recently talked to LCGC about best practices he and his team have established for developing such methods, including approaches to meeting a variety of requirements of regulatory bodies, simplifying sample preparation, dealing with matrix effects, choosing an ionization method, and streamlining method development.

When you are developing environmental methods for the registration or re-registration with the U.S. Environmental Protection Agency (EPA) of a new pesticide, what exactly do you have to demonstrate?

We must demonstrate that the methods we develop extract the environmental residue of concern from soil or sediment and that the residue is accurately quantified. To demonstrate the performance of the extraction method, we treat soil samples with radiolabeled compounds and age them in conditions representative of the environment. Aging the treated soil or sediment allows for the environmental metabolites to form and for the soil to become representative of a sample collected from the environment. We then extract the aged samples and analyze the radioactivity in the extract and the amount of radioactivity remaining in the soil. We test different extraction solvents, extraction techniques (for example, bead mill, sonication, or microwave), and the number of extractions conducted until close to all of the significant residue is extracted from the sample.

Once we have an extraction method, we fortify untreated control soil or sediment samples with known amounts of the analytes of interest. We then extract and analyze these samples and compare the concentration determined using the method to the known amount added to the control samples. The amount determined must be between 70% and 120% of the amount added for the method performance to be acceptable.

In addition to meeting the requirements of the U.S. EPA, do you also have to meet requirements for other regulatory bodies, such as those of other countries, if your products will be sold abroad, or of individual states within the United States? If so, how do you balance meeting all the requirements?

In an attempt to minimize additional method development work, we develop our methods to meet the most conservative requirements and test our methods on soil collected from all parts of the world. Currently, the European Union (EU) has some of the most conservative requirements for environmental methods. These requirements are described in the SANCO 825 Revision 8.1 guidance document (1). Once validated, the environmental methods can be sent to support compound registrations anywhere. An example is the residue method for chlorantraniliprole in crops (2). This method was validated on 21 different crops at a limit of quantitation of 0.010 mg/kg. This method has been accepted by regulatory agencies around the world for data collection and maximum residue limit (MRL) enforcement.

What are typically the biggest challenges in developing methods for detecting a pesticide and its metabolites in soil or sediment? What are the biggest challenges for detecting them in water?

Minimizing matrix effects is a major challenge when developing environmental methods. Since our methods are intended to analyze samples from grower fields, a suitable control sample will not always be available. Therefore, preparing standards in untreated control extracts may not always be an option. Moreover, the U.S. EPA prohibits the use of matrix-matched standards in all monitoring and enforcement methods (3).

Developing selective cleanup steps is one way to deal with matrix effects. However, the number and diversity of metabolites in the methods and the low limit of quantitation (1.0 µg/kg or below) makes method development a challenging task. The diversity of metabolites makes it difficult to develop one cleanup procedure capable of removing co-extracts while keeping all of the analytes of interest in a single extract. Keeping all of the compounds in a single extract limits the selectivity of the cleanup procedure.

Developing chromatographic separations using ultrahigh-pressure liquid chromatography (UHPLC) columns or solid-core particles can help minimize matrix effects as well. The sharp peak shape these columns produce lowers the instrument detection level, allowing additional dilution of the extracts. Dilution is perhaps the best way to minimize matrix effects. Instrument manufacturers continue to produce faster, more sensitive, and more-rugged instruments that have allowed us to simplify and streamline our methods. The speed of the newest generation of instruments allow for positive–negative switching without significant loss of sensitivity. This capability has removed the need to separate positive- and negative-ionizing compounds chromatographically or to analyze them in multiple chromatographic runs.

Water samples, although less complicated than soil or sediment, can be just as challenging. Water methods usually have a limit of quantitation of 0.10 µg/L or lower. For methods that include many metabolites, the analytes may need to be extracted from the water samples using solid-phase extraction (SPE) or a liquid–liquid partition step. Once the extract is concentrated, a solvent-exchange step may be needed before analysis. At the low levels analyzed in these methods, minor water contaminants can complicate quantitative analysis.

Over the years, have you developed best practices or streamlined approaches to developing these methods?

When developing the extract purification procedures, we tend to use a systematic approach. Before extracting any samples, we test evaporation and reconstitution steps, liquid–liquid partitions, and SPE procedures. When developing SPE procedures, we filter the analytes through columns in a variety of solvents to determine when they are retained and when they are eluted. Once we retain the analytes on a cartridge, we wash the cartridges with progressively stronger solvents until we have a complete profile of the properties for all analytes. Having all of this information allows us to understand how the analytes behave and to piece together an efficient and effective cleanup procedure.

We prefer to include all of the known metabolites in the methods. If the compound is not detected in the terrestrial field soil dissipation studies or if it does not show any adverse ecotoxicology effects, it can be removed from the method. We refer to this approach as comprehensive method development. We validate our methods in this manner because the addition of a new metabolite to an existing method often results in completely reworking the method, which can be time- and resource-intensive.

In environmental analysis, a challenge is often the complex matrix, which requires effective sample cleanup and preparation. Do you have “go-to” sample cleanup or preparation approaches for certain classes of products?

When developing our methods, we usually start with the most difficult soil or water samples. The idea is that if the method works for the most complex samples it will perform well for the other samples. For soil samples, we start with a high clay, high organic matter soil. We have found this combination results in an extract that is very difficult to purify and analyze. For water samples, we usually start with a pond-water sample.

The methods developed are based on the analytes included in the analysis. When developing methods for polar metabolites, some of the reversed-phase polymer SPE cartridges can be very effective at concentrating the sample extracts. We usually try to develop cleanup procedures that complement the separation and detection methods. If we are using reversed-phase LC we will try to develop an ion-exchange cleanup. If we are using an alkyl SPE cartridge (such as C18 or C8) for the cleanup step, we will develop a separation using a phenyl or biphenyl column. The overall goal is to minimize matrix effects by taking advantage of multiple physical-chemical properties of the analytes.

What percentage of your methods use gas chromatography (GC) and what percentage use LC? Has there been any change in recent years in that balance?

Almost all of the methods we develop are LC methods. Many of our active ingredients are thermally labile, limiting the use of GC analysis. The inclusion of multiple metabolites to these methods also limits the amount of GC analysis we conduct. Often, the metabolites we are analyzing are small polar alcohols or weak acids that are not amenable to GC analysis without derivatization. Although derivatization procedures can be developed, they can be time consuming and add complexity to the methods. It is also worth mentioning that relative to LC analyses, we have generally observed more severe matrix effects when conducting GC analyses.

What type of mass spectrometry (MS) detection do you typically use?

We typically use LC–MS/MS detection on triple-quadrupole instruments. Given that we are analyzing a limited number of known compounds using a reference standard, we can set up several multiple-reaction monitoring (MRM) transitions at the retention time of each analyte. In addition to being very sensitive, this approach allows for confirmation and quantitation during a single analysis. An added benefit is the availability of triple-quadrupole instruments in contract and monitoring laboratories. Using similar equipment allows for our methods to be transferred and revalidated at the laboratories performing the analysis with minimal modifications.

When do you use atmospheric pressure chemical ionization (APCI) MS, rather than electrospray ionization (ESI)?

When developing a new method, we usually start with ESI because often it is more sensitive than APCI. If we determine matrix effects are affecting method performance, we attempt to develop a cleanup procedure that is efficient and effective at minimizing the matrix effects. If, because of the number or diversity of the analytes, the cleanup procedure is not effective, is not rugged, or is very complicated, we switch to the APCI ion source. Although less sensitive, APCI usually does not exhibit the same degree of matrix effects as ESI. Given the reduced sensitivity of APCI, we adjust the injection volume, aliquot factor, or the sample’s final volume to reach the required detection level (2). Not all of the compounds we monitor can be ionized using APCI because of the increased temperature of the ion source and the gas-phase ionization mechanism. For compounds that are not amenable to APCI we return to ESI and look for new extract cleanup steps or better chromatographic separations until a robust method is developed.

How do you balance the need for sample preparation methods that are effective but not overly complicated or time consuming?

We need to strike a balance between the amount of sample cleanup, the time required to conduct the analysis, and the overall method performance. Cleanup can be time consuming and tedious work. However, without adequate cleanup, a method will perform well for only a limited number of sample types because of matrix effects or could result in false positives as a result of coeluted peaks. Reducing sample cleanup in favor of longer chromatographic separations limits the number of samples that can be analyzed per instrument each day.

Because of the large sample size (2–5 g) required to produce a representative soil or sediment sample, we have not implemented the 96-well format or other automated sample preparation approaches. We have seen significant improvements in efficiency using bead mill extractors, however. Bead mill extractors show excellent extraction efficiency of incurred residues and require less solvent per sample, and all of the equipment used is disposable, reducing the probability of sample contamination. The biggest advantage of bead mill extractors is the amount of time required to perform an extraction. An extraction requiring 20–30 min on a wrist action shaker or in a sonicating bath can be completed in 2–3 min using a bead mill.

Our goal is to develop a method with an efficient and rugged cleanup procedure and a set of chromatographic conditions that allow for adequate sample throughput without compromising the accuracy of the analysis.

References

(1) European Commission, Directorate General Health and Consumer Protection. “Guidance Document on Residue Analytical Methods,” SANCO/825/00 rev. 8.1, November 16, 2010.

(2) J. Grant, C.A. Rodgers, C.D. Chickering, S.J. Hill, and J.J. Stry, J. AOAC Int. 93(4), 1293–1301 (2010).

(3) U.S. EPA Ecological Effects Test Guidelines: OCSPP 850.6100: Environmental Chemistry Methods and Associated Independent Laboratory Validation.


James StryJames Stry is a principal investigator in the Regulatory Analytical Group at FMC Agricultural Solutions.Before joining FMC in 2017, he was with DuPont Crop Protection for 20 years. He is responsible for monitoring the global regulatory environment as it pertains to the residue and environmental analysis of crop protection compounds.In addition, he also maintains an active laboratory program developing new residue and environmental methods to meet regulatory requirements.Stry graduated from the State University of New York at Buffalo with a PhD in physical chemistry.

 

Source link

Healthcare Analytical Testing Services Market – Global Forecast to 2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Healthcare
Analytical Testing Services Market by Type (Method Validation,
Environmental Monitoring, Bioanalytical Services, Stability, Raw
Materials, & Microbial Testing), End User (Pharmaceutical, Medical
Device Companies) – Global Forecast to 2023”
report has been
added to ResearchAndMarkets.com’s offering.

The Healthcare Analytical Testing Services Market is Expected to Reach
USD 5.97 Billion by 2023 from an Estimated USD 3.43 Billion in 2018, at
a CAGR of 11.7%.

The shift of focus towards analytical testing of biologics and
biosimilars, increasing outsourcing of analytical testing by
pharmaceutical companies, increasing acceptance of the QbD approach in
pharma research/manufacturing, and adoption of FTE contracts in R&D
outsourcing are the major factors driving the growth of the healthcare
analytical testing services market.

However, factors such as the pricing pressure faced by market players
and shortage of skilled professionals in the healthcare analytical
testing services industry are limiting the adoption of healthcare
analytical testing services up to some extent during the forecast period.

North America held the largest share of the global healthcare analytical
testing services market in 2017. On the other hand, the APAC region is
expected to witness the highest CAGR during the forecast period, due to
the increasing R&D funding, growing number of CROs, and favorable
government initiatives to promote pharmaceutical and biopharmaceutical
industries in several APAC countries.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Insights

7 Healthcare Analytical Testing Services Market, By Type

8 Healthcare Analytical Testing Services Market, By End User

9 Healthcare Analytical Testing Services Market, By Region

10 Competitive Landscape

11 Company Profiles

  • Charles River
  • Envigo
  • Eurofins Scientific
  • Exova
  • Intertek
  • Labcorp
  • MPI Research
  • Merck KGaA
  • Pace Analytical
  • Pharmaceutical Product Development, LLC (PPD)
  • SGS
  • Source Bioscience
  • Wuxi Pharmatech

For more information about this report visit https://ift.tt/2qCnfVa

Source link